ADVANCED BIOMED INC (ADVB) Stock Price, Forecast & Analysis
USA - NASDAQ:ADVB - US00752P1049 - Common Stock
ADVB Key Statistics, Chart & Performance
The current stock price of ADVB is 0.4214 USD. In the past month the price decreased by -6.07%.
ADVB Latest News, Press Relases and Analysis
ADVB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 17.97 | 14.36B | ||
| SOLV | SOLVENTUM CORP | 13.63 | 14.04B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.02 | 9.83B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.69 | 5.00B | ||
| HAE | HAEMONETICS CORP/MASS | 15.73 | 3.64B | ||
| LNTH | LANTHEUS HOLDINGS INC | 9.08 | 3.68B | ||
| ICUI | ICU MEDICAL INC | 16.71 | 3.29B | ||
| XRAY | DENTSPLY SIRONA INC | 6.41 | 2.02B | ||
| UFPT | UFP TECHNOLOGIES INC | 25.51 | 1.70B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.33B | ||
| NEOG | NEOGEN CORP | 18.82 | 1.23B | ||
| EMBC | EMBECTA CORP | 4.77 | 814.77M |
Related stock screener links
About ADVB
Company Profile
Advanced Biomed, Inc. operates as a holding company with interests in developing biochip technologies. The company is headquartered in Reno, Nevada and currently employs 31 full-time employees. The company went IPO on 2025-03-06. The firm is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. The company has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The firm offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip.
Company Info
ADVANCED BIOMED INC
401 Ryland St, Ste 200-A
Reno NEVADA US
Employees: 31
Phone: 1862120510823
ADVANCED BIOMED INC / ADVB FAQ
Can you describe the business of ADVANCED BIOMED INC?
Advanced Biomed, Inc. operates as a holding company with interests in developing biochip technologies. The company is headquartered in Reno, Nevada and currently employs 31 full-time employees. The company went IPO on 2025-03-06. The firm is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. The company has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The firm offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip.
What is the stock price of ADVANCED BIOMED INC today?
The current stock price of ADVB is 0.4214 USD. The price increased by 1.96% in the last trading session.
What is the dividend status of ADVANCED BIOMED INC?
ADVB does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADVB stock?
ADVB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy ADVB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADVB.
Can you provide the market cap for ADVANCED BIOMED INC?
ADVANCED BIOMED INC (ADVB) has a market capitalization of 9.12M USD. This makes ADVB a Nano Cap stock.
ADVB Technical Analysis
ADVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADVB. While ADVB seems to be doing ok healthwise, there are quite some concerns on its profitability.
ADVB Financial Highlights
Over the last trailing twelve months ADVB reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS decreased by -23.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.04% | ||
| ROE | -93.71% | ||
| Debt/Equity | 0 |